Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 1
1964 2
1968 1
1971 1
1972 2
1973 1
1976 1
2000 1
2001 4
2002 4
2003 2
2004 5
2005 6
2006 3
2007 6
2008 13
2009 7
2010 7
2011 10
2012 11
2013 2
2014 6
2015 10
2016 6
2017 8
2018 14
2019 10
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

144 results
Results by year
Filters applied: . Clear all
Page 1
[Oncolytic coxsackievirus therapy as an immunostimulator].
Miyamoto S, Sagara M, Kohara H, Tani K. Miyamoto S, et al. Rinsho Ketsueki. 2017;58(8):977-982. doi: 10.11406/rinketsu.58.977. Rinsho Ketsueki. 2017. PMID: 28883283 Review. Japanese.
Recently, the active development of oncolytic virotherapy has gathered attention. Enterovirus research seeks to better understand its pathogenicity. In particular, coxsackievirus A21 (CVA21) is a promising candidate for oncolytic virotherapy, and thus …
Recently, the active development of oncolytic virotherapy has gathered attention. Enterovirus research seeks to better underst …
Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma.
Deng H, Liu H, de Silva T, Xue Y, Mohamud Y, Ng CS, Qu J, Zhang J, Jia WWG, Lockwood WW, Luo H. Deng H, et al. Mol Ther Oncolytics. 2019 Jul 23;14:266-278. doi: 10.1016/j.omto.2019.07.003. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31463367 Free PMC article.
The current study explored the possibility to develop coxsackievirus type B3 (CVB3) as an oncolytic agent for the treatment of KRAS (mut) lung adenocarcinoma. ...
The current study explored the possibility to develop coxsackievirus type B3 (CVB3) as an oncolytic agent for the treatment of …
Oncolytic viruses: From bench to bedside with a focus on safety.
Buijs PR, Verhagen JH, van Eijck CH, van den Hoogen BG. Buijs PR, et al. Hum Vaccin Immunother. 2015;11(7):1573-84. doi: 10.1080/21645515.2015.1037058. Hum Vaccin Immunother. 2015. PMID: 25996182 Free PMC article. Review.
Oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents. Several viruses have undergone evaluation in clinical trials in the last decades, and the first agent is about to be approved to be used as a novel cancer therapy modality. In the current rev
Oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents. Several viruses have undergone evaluation in clinic
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM, Friedman GK, Cassady KA, Markert JM. Foreman PM, et al. Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Neurotherapeutics. 2017. PMID: 28265902 Free PMC article. Review.
Oncolytic viruses are designed to selectively target, infect, and replicate in tumor cells, while sparing surrounding normal brain. ...Oncolytic viral therapy for glioma remains promising and will undoubtedly impact the future of patient care....
Oncolytic viruses are designed to selectively target, infect, and replicate in tumor cells, while sparing surrounding normal brain. .
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, Butler R, Shafren D, Au G, Knowles M, Harrington K, Vile R, Melcher A, Pandha H. Annels NE, et al. Mol Ther Oncolytics. 2018 Feb 14;9:1-12. doi: 10.1016/j.omto.2018.02.001. eCollection 2018 Jun 29. Mol Ther Oncolytics. 2018. PMID: 29989024 Free PMC article.
As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 …
As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) present …
The advent of oncolytic virotherapy in oncology: The Rigvir® story.
Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. Alberts P, et al. Eur J Pharmacol. 2018 Oct 15;837:117-126. doi: 10.1016/j.ejphar.2018.08.042. Epub 2018 Sep 1. Eur J Pharmacol. 2018. PMID: 30179611 Free article. Review.
Oncolytic viruses are a fast-developing cancer treatment field. Numerous viruses have been tested in clinical trials and three are approved. ...In conclusion, Rigvir is an oncotropic and oncolytic virus for treatment of melanoma; the results will be confirmed and up
Oncolytic viruses are a fast-developing cancer treatment field. Numerous viruses have been tested in clinical trials and three are ap
Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3.
Jia Y, Miyamoto S, Soda Y, Takishima Y, Sagara M, Liao J, Hirose L, Hijikata Y, Miura Y, Hara K, Iwanaga A, Ota Y, Tani K. Jia Y, et al. Mol Ther Oncolytics. 2019 Jan 25;12:246-258. doi: 10.1016/j.omto.2019.01.003. eCollection 2019 Mar 29. Mol Ther Oncolytics. 2019. PMID: 30891489 Free PMC article.
Oncolytic virotherapies have emerged as new modalities for cancer treatment. We previously reported that coxsackievirus B3 (CVB3) is a novel oncolytic virus (OV) with a strong ability to lyse human non-small cell lung cancer cells; however, its non-specific t
Oncolytic virotherapies have emerged as new modalities for cancer treatment. We previously reported that coxsackievirus B3 (CV
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Desjardins A, et al. N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26. N Engl J Med. 2018. PMID: 29943666 Free PMC article. Clinical Trial.
Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y, Wang W, Wan J, Yang Y, Fu W, Pan D, Cai L, Cheng T, Huang X, Wang Y. Lin Y, et al. Virol J. 2018 Apr 10;15(1):65. doi: 10.1186/s12985-018-0975-x. Virol J. 2018. PMID: 29631630 Free PMC article.
Oncolytic virotherapy offers a novel promising option of cancer treatment and has demonstrated good efficacy in preclinical models and clinical trials. However, only few oncolytic viruses have been tested for EC treatment. In this study, the potential of an oncol
Oncolytic virotherapy offers a novel promising option of cancer treatment and has demonstrated good efficacy in preclinical models an
Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
Hazini A, Pryshliak M, Brückner V, Klingel K, Sauter M, Pinkert S, Kurreck J, Fechner H. Hazini A, et al. Hum Gene Ther. 2018 Nov;29(11):1301-1314. doi: 10.1089/hum.2018.036. Epub 2018 Jun 20. Hum Gene Ther. 2018. PMID: 29739251
Coxsackievirus B3 (CVB3), a single-stranded RNA virus of the picornavirus family, has been described as a novel oncolytic virus. ...The data demonstrate the potential of PD as a new oncolytic virus and HS-binding of PD as a key feature of oncolytic act
Coxsackievirus B3 (CVB3), a single-stranded RNA virus of the picornavirus family, has been described as a novel oncolytic viru
144 results
Jump to page
Feedback